Temozolomide Therapy

Temozolomide Therapy is a chemotherapeutic regimen that involves the systemic administration of temozolomide, a DNA-alkylating agent, to selectively induce tumor cell death in high-grade gliomas through methylation of guanine residues at the O6 position.

3.3K

Publications

260K

Citations

19.1K

Authors

3.6K

Institutions

Publications per year

2017–2026

1.3K

Authors

19.1K

  1. MW
    Michael Weller

    University Hospital of Zurich, Switzerland

    79 publications · 54.7K citations

    50

    h-index

  2. WW
    Wolfgang Wick

    Heidelberg University, Germany

    61 publications · 14.4K citations

    43

    h-index

  3. RS
    Roger Stupp

    University of Lausanne, Switzerland

    57 publications · 52.9K citations

    40

    h-index

  4. AA
    Alba A. Brandes

    Istituti di Ricovero e Cura a Carattere Scientifico, Italy

    58 publications · 43.1K citations

    39

    h-index

  5. MJ
    Martin J. van den Bent

    Erasmus MC Cancer Institute, Netherlands

    54 publications · 36.3K citations

    36

    h-index

1–5 of 19.1K

Venues

  1. Journal of Clinical Oncology

    181 publications · 25K citations

    77

    h-index

  2. Neuro-Oncology

    156 publications · 13.6K citations

    75

    h-index

  3. Clinical Cancer Research

    90 publications · 12.6K citations

    63

    h-index

  4. Journal of Neuro-Oncology

    216 publications · 11.4K citations

    61

    h-index

  5. PubMed

    Repository · 127 publications · 7.6K citations

    47

    h-index

1–5